



Fig. S1: MYOM2 mutations in patients with hypertrophic cardiomyopathy (HCM). Sequence 
electropherograms representing the four mutations in the MYOM2 gene. The panel shows the 
mutated sequence demonstrating heterozygosity in three of them (HCM-01, HCM-02, HCM-04). In 
patient HCM-03, a homozygous mutation was found. The arrow points to the mutated nucleotide. 
  



































Fig. S2: Analysis of phosphorylation status and protein levels of native myocardial tissue from 
HCM-02 and controls. (A) Protein phosphorylation was analyzed by calculating the ratio of Pro-Q 
Diamond staining (phosphorylated protein) vs. SYPRO Ruby staining (total amount of protein; Fig. 2B) 
for each band, respectively, as described in Kraft et al., J Mol Cell Cardiol 57 (2013). (B) For analysis of 
relative protein quantities, the bands of the respective proteins on the SYPRO Ruby stained gels (Fig. 
2B) were densitometrically analyzed and normalized to the α-actinin signal in the same lane. n=5 
different controls; n=5 independent analyses for HCM-02; error bars indicate SD; *p<0.05; **p<0.01, 
***p<0.001 (Student’s t-test).  


































Fig. S3: Amino acid alignments of Drosophila orthologs CG14964, bt and sls and human MYOM2 and 
TTN. (A) Alignment of CG14964 and MYOM2 show that both proteins are composed of fibronectin type 
III-like (FN3) and immunoglobulin-like (Ig) domains. Arrows indicate mutations in TOF (blue) and HCM 
patients (red), respectively. (B) Alignment of bent (bt) and MYOM2 comprises a different structure 
organization with many FN3 domains for bt spanning most of the protein while MYOM2 contains only 
five FN3 domains in the center. (C) Alignment of bt with TTN shows the conservation of intercalation 
of FN3 and Ig domains. (D) Alignment of sallimus (sls) also shows the conserved intercalation of FN3 
and Ig domains. Alignments indicated in red mainly consist of FN3 and Ig-like domains. 


































Fig. S4: Protein alignments of CG14964 with (A) MYPHL, (B) MYBPC3 and (C) MYBPH. Alignments 
show structural similarities between fly and human proteins. 
  


































Fig. S5: RNAscope in situ for CG14964 in (A) Hand4.2 > GD control and (B) Hand4.2 > CG14964HMC06031 
RNAi. Note that expression is detectable in ventral layer muscle syncytium (arrowheads) but absent in 









































































Fig. S6: CG14964 genomic locus and knockdown efficiency in different fly mutants. (A-B) RT-qPCR 
results performed in a heart-specific manner showing a knockdown of CG14964 in (A) CG14964i-GD 
and (B) CG14964i-T3 3 weeks old adult hearts where the knockdown is expressed in heart only (Hand4.2-
Gal4) or muscle and heart (Mef2-Gal4). (C-D) Quantification of the amount of CG14964 transcripts 
counted in body wall muscles (C) or heart (D) of fixed abdominal samples from Hand4.2>CG14964i-GD 
and Hand4.2>CG14964i-T3 adult flies normalized to control flies, using RNAscope (ACDbio). (E) 
Organization of the genomic locus of CG14964 including CRIMIC insertion site and localization of qPCR 
primers used. (F) Genomic region covered by Df(3L)BSC672 deficiency spanning multiple genes 
including CG14964 (red). (G-I) RT-qPCR results performed from RNA isolated from whole (G) 
heterozygous deficiency flies, (H) homozygous CRIMIC insertion flies and (I) CRIMIC/Df 
transheterozygotes.  
  

































Fig. S7: Cardiac-specific knockdown of CG14964 leads to heart defects in the adult fly. Cardiac 
functional analysis on 3 weeks old flies harboring a knockdown of CG14964 by using CG14964i-T3 
shows a trend towards constricted hearts. Shown is the median with interquartile range. Statistics 
based on one-way ANOVA, Tukey post-hoc test with *p<0.05, ***p<0.01 and ***p<0.001. 
  

































Fig. S8: Representative image showing intact sarcomere structure of 1-week old homozygous 
CG14964 CRIMIC mutant (potential null mutant) stained for F-Actin (red) and Mhc (green). 































Fig. S9: CG14964 CRIMIC mutants have higher Mhc protein levels compared to controls. Mhc 
staining of 1-week female CG14964CRIMIC flies and controls were stained for Mhc and imaged using 
identical settings. (A) Mutant hearts have a stronger Mhc signal compared to controls in both, 
cardiomyocytes and ventral layer muscles (VLM). (B) Mean gray value (intensity) of 5 ROIs per cell 
type and fly were measured using ImageJ. Graph displays average of mean Mhc intensities per fly 
Statistics: unpaired t-test. *p≤0.05, **p≤0.005. CG14964CRIMIC indicates homozygous CG14964 CRIMIC 
mutants; all intensity values are artificial units. 


































Fig. S10: Overexpression of human MYOM2 using Mef2-Gal4 driver. Tissues are stained for hMYOM2 
and pericardin probes. Cardiomyocytes show a clear signal of hMYOM2 (arrowheads), whereas 
pericardin mRNA is detected in pericardial cells (curved arrows).  

















































HCM-01 F HOCM 31 50 II Yes Yes 
HCM-02 M HOCM 19 52 III Yes Yes 
HCM-03 M HOCM 50 56 II Yes No 


















HCM-01 No 20 43 16 12 Yes Medication 
HCM-02 No 32 52 15 14 Yes Myectomy 
HCM-03 No 17 50 17 14 Yes Medication 
HCM-04 No 17 48 23 16 Yes Septal ablation 
 
Table S1. Clinical data of the MYOM2 mutation carriers with hypertrophic cardiomyopathy (HCM). 
ECG: Electrocardiogram; M: Male; F: Female; NYHA: New York Heart Association; LVEDP: Left 
ventricular end-diastolic pressure; LVEDD: Left ventricular end-diastolic diameter; IVS: Interventricular 






































Age (years) sex 
3.149 56 m 
3.073 41 w 
5.138 23 m 
5.140 31 w 
6.008 40 m 
 
Table S2. Details about the samples from the interventricular septum of donor hearts. SHB: Sydney 
Heart Bank. 
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